



# Lotus Eye Hospital And Institute Limited

CIN No. : L85110TZ1997PLC007783

770/12, Avinashi Road, Civil Aerodrome Post, Coimbatore - 641 014.

Tel : 0422 - 4229900, 4229999

## R.S.PURAM

155B, East Periasamy Road, Near Chinthamani,  
North Coimbatore, R.S.Puram, Coimbatore - 641 002.  
Ph : 0422 - 4239900, 4239999

## SARAVANAMPATTI

86/1, Site No.2, TRM Avenue, Sathy Road,  
Saravanampatti, Coimbatore - 641 035.  
Ph : 0422 - 2210021

E-mail : [info@lotuseye.org](mailto:info@lotuseye.org)

Website : [www.lotuseye.org](http://www.lotuseye.org)

February 12, 2025

<b>BSE Limited</b> <b>PhirozeJeejeebhoy Towers</b> <b>Dalal Street</b> <b>Mumbai- 400001</b> <b>Scrip Code: 532998</b>	<b>National Stock Exchange of India Limited</b> <b>5th Floor, Exchange Plaza</b> <b>Bandra (East)</b> <b>Mumbai – 400 051</b> <b>Scrip Code: LOTUSEYE</b>
--	---

Dear Sir/Madam

### Sub: Outcome of Board Meeting held on February 12th 2025

In terms of Regulation 30 read with Part A Schedule III of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015, we wish to inform you that the Board of Directors of the Company at its meeting held on February 12, 2025 has transacted the following business:

- 1) Approved unaudited standalone results for the quarter and year ended December 31<sup>st</sup>, 2024;

The Board meeting commenced by ..05:00 PM ended by .....06:25 PM

We request you to please take the same on your record.

Yours Faithfully

For Lotus Eye Hospital and Institute Limited

M Achuth Menon

Company secretary & Compliance Officer

Membership No – A63980



**Lotus Eye Hospital and Institute Limited**

CIN: L85110TZ1997PLC007783

Registered office: 770/12, Avinashi road, Aerodrome post, Coimbatore 641 014

Phone no: 0422-4229900, Fax: 0422-4229933, E-mail: companysecretary@lotuseye.org, Website: www.lotuseye.org

**Statement of Un-audited Financial Results for the Quarter/ Nine months ended December 31, 2024**

(Rs. in lakhs)

Sr. No.	Particulars	Quarter Ended			Nine months ended		Year Ended
		December 31, 2024	September 30, 2024	December 31, 2023	December 31, 2024	December 31, 2023	March 31, 2024
		(Un-audited)			(Un-audited)		(Audited)
	<b>Income:</b>						
I.	Revenue from operations	1,224.69	1,291.24	1202.98	3,805.00	3,732.66	4,820.99
II.	Other income	22.08	26.45	34.72	79.14	90.30	130.27
<b>III.</b>	<b>Total Income (I+II)</b>	<b>1,246.77</b>	<b>1,317.69</b>	<b>1,237.70</b>	<b>3,884.14</b>	<b>3,822.96</b>	<b>4,951.26</b>
IV.	<b>Expenses:</b>						
	(a) Cost of materials consumed	195.34	225.65	213.93	635.77	665.50	844.23
	(b) Purchase of stock-in-trade	186.49	187.79	169.72	576.52	545.92	705.05
	(c) Changes in inventories	(3.78)	(7.69)	(1.97)	(43.74)	(21.23)	(17.18)
	(d) Service expenses	238.98	239.38	187.03	703.83	572.42	761.14
	(e) Employee benefit expense	295.62	297.68	252.98	874.09	723.85	981.01
	(f) Finance costs	12.63	7.75	3.62	26.05	6.57	9.74
	(g) Depreciation and amortization expense	130.69	122.56	98.11	358.92	260.55	372.78
	(h) Other expenses	233.15	233.82	223.47	698.63	668.95	893.71
	<b>Total expenses (IV)</b>	<b>1,289.12</b>	<b>1,306.94</b>	<b>1,146.89</b>	<b>3,830.07</b>	<b>3,422.53</b>	<b>4,550.48</b>
V.	<b>Profit/(loss) before exceptional items and tax (III-IV)</b>	<b>(42.35)</b>	<b>10.75</b>	<b>90.81</b>	<b>54.07</b>	<b>400.43</b>	<b>400.78</b>
VI.	<b>Exceptional items</b>	<b>(0.23)</b>	<b>0.25</b>	<b>(0.98)</b>	<b>(0.02)</b>	<b>0.41</b>	<b>0.59</b>
<b>VII.</b>	<b>Profit/(loss) before tax (V+VI)</b>	<b>(42.58)</b>	<b>11.00</b>	<b>89.83</b>	<b>54.05</b>	<b>400.84</b>	<b>401.37</b>
VIII.	<b>Tax expenses</b>						
	(a) Current tax	(9.83)	9.69	23.93	23.46	107.04	100.19
	(b) Deferred tax	(8.84)	(8.96)	0.23	(18.10)	4.78	9.73
	<b>Total tax expense (VIII)</b>	<b>(18.67)</b>	<b>0.73</b>	<b>24.16</b>	<b>5.36</b>	<b>111.82</b>	<b>109.92</b>
<b>IX.</b>	<b>Net profit/(loss) for the period (VII-VIII)</b>	<b>(23.91)</b>	<b>10.27</b>	<b>65.67</b>	<b>48.69</b>	<b>289.02</b>	<b>291.45</b>
X.	<b>Other comprehensive income, net of income tax</b>						
	A. Items that will not be reclassified to profit or loss						
	- Remeasurement of post-employment defined benefit plans	(2.00)	(2.00)	(2.00)	(6.00)	(6.00)	(6.22)
	- Income tax on the above item	0.56	0.55	0.56	1.67	1.67	1.73
	B. Items that will be reclassified to profit or loss	-	-	-	-	-	-
	<b>Total other comprehensive income, net of income tax (X)</b>	<b>(1.44)</b>	<b>(1.45)</b>	<b>(1.44)</b>	<b>(4.33)</b>	<b>(4.33)</b>	<b>(4.49)</b>
<b>XI.</b>	<b>Total comprehensive income for the period (IX + X)</b>	<b>(25.35)</b>	<b>8.82</b>	<b>64.23</b>	<b>44.36</b>	<b>284.69</b>	<b>286.96</b>
XII.	<b>Paid-up equity share capital (face value of Rs. 10/- each)</b>	2,079.63	2,079.63	2,079.63	2,079.63	2,079.63	2,079.63
XIII.	<b>Earning per equity share: (of Rs. 10/-) (Not annualised):</b>						
	(1) Basic (In Rs.)	(0.11)	0.05	0.32	0.23	1.39	1.40
	(2) Diluted (In Rs.)	(0.11)	0.05	0.32	0.23	1.39	1.40

For Lotus Eye Hospital & Institute Limited


*S. Sangeetha*  
Ms. S. SANGEETHA  
Managing Director - DIN : 01859252

**Notes :**

1. The above financial results have been reviewed by the Audit committee and approved by the Board of Directors at their meeting held on February 12, 2025.
2. Exceptional items represent the profit/(loss) on sale of property, plant & equipment.
3. Figures of the previous periods have been regrouped and reclassified to confirm to the classification of current period, wherever necessary.

Coimbatore,  
February 12, 2025.

For Lotus Eye Hospital & Institute Limited



Ms. S. SANGEETHA  
Managing Director - DIN : 01859252

To  
The Board of Directors,  
Lotus Eye Hospital and Institute Limited,  
Coimbatore.

**Limited review report for the Quarter/Nine months ended December 31, 2024**

1. We have reviewed the accompanying statement of unaudited financial results of Lotus Eye Hospital and Institute Limited ("the Company") for the quarter/nine months ended December 31, 2024, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.
2. This statement which is the responsibility of the Company's management and approved by the Board of Directors at their meeting on February 12, 2025, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the aforesaid Indian Accounting Standards and other recognized accounting practices and policies, have not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Coimbatore,  
February 12, 2025.



For Anbarasu & Jalapathi  
Chartered Accountants  
Firm Registration No.: 010795S



CA. K. Jalapathi  
Partner

Membership No.: 214823  
UDIN: 25214823BMUJY83964